We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aadi Bioscience Inc | NASDAQ:AADI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -2.12% | 2.77 | 2.74 | 3.10 | 2.90 | 2.72 | 2.85 | 67,105 | 22:59:00 |
From Aug 2024 to Feb 2025
LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.
About Aadi BioscienceÂ
Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact:
IR@aadibio.comÂ
View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-third-quarter-2024-results-and-corporate-update-302291958.html
SOURCE Aadi Bioscience
Copyright 2024 PR Newswire
1 Year Aadi Bioscience Chart |
1 Month Aadi Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
